Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
D-TACE + lenvatinib + tislelizumab
- Development stage
- Unknown
- Lead developer
- Wen Li
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Device-based Delivery → Drug Delivery Systems
- Administration
- Intra-arterial, Oral, Intravenous
01
Overview
D-TACE + lenvatinib + tislelizumab is an investigational combination regimen being evaluated for the treatment of advanced unresectable hepatocellular carcinoma (HCC). The regimen integrates three distinct therapeutic modalities: Drug-eluting Bead Transarterial Chemoembolization (D-TACE) using pirarubicin-loaded CalliSpheres (100-300 µm), the oral multi-kinase inhibitor lenvatinib, and the intravenous anti-PD-1 monoclonal antibody tislelizumab. D-TACE provides a dual effect by delivering high-dose chemotherapy (pirarubicin) directly to the tumor while simultaneously inducing ischemia through embolization. Lenvatinib targets multiple tyrosine kinases, including VEGFR1-3 and FGFR1-4, to inhibit angiogenesis and lymphangiogenesis. Tislelizumab is a humanized IgG4 monoclonal antibody that binds to PD-1, preventing its interaction with PD-L1 and PD-L2 to enhance the immune system's ability to detect and destroy cancer cells. This triple-modality approach is currently being compared against HAIC-based combination therapies in clinical trials led by investigator Wen Li.
- Brand names
- CalliSpheres
- Other names
- D-TACE plus lenvatinib and tislelizumabD-TACE-L-T
02
Targets
DNATOP2A (DNA topoisomerase II)FGFR1 (Fibroblast growth factor receptor 1)FGFR2 (Keratinocyte growth factor receptor)FGFR3 (Fibroblast growth factor receptor 3)FGFR4 (Fibroblast growth factor receptor 4)KIT (c-KIT proto-oncogene receptor tyrosine kinase)PDCD1 (Programmed cell death protein 1 receptor)PDGFRA (Platelet-derived growth factor receptor alpha)RET (Rearranged during transfection receptor tyrosine kinase)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)VEGFR4 (Vascular endothelial growth factor Receptor-3)
Beyond the preview
Go deeper on D-TACE + lenvatinib + tislelizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on D-TACE + lenvatinib + tislelizumab.